New drug cocktail aims to stall advanced lung cancer

NCT ID NCT05798663

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 27 times

Summary

This study tests whether adding an experimental immunotherapy drug (tiragolumab) to standard immunotherapy (atezolizumab) plus chemoradiation helps people with stage III lung cancer live longer without the disease getting worse. About 178 participants will receive either the two-drug combo or atezolizumab alone, alongside standard treatment. The goal is to see which approach better delays cancer progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hematology Oncology Associates of Central New York, P.C.

    East Syracuse, New York, 13057, United States

  • Kaiser Permanente Oakland Medical Center

    Oakland, California, 94611, United States

  • Kaiser Permanente Roseville Medical Center

    Roseville, California, 95661, United States

  • Kaiser Permanente San Francisco Medical Center

    San Francisco, California, 94115, United States

  • Kaiser Permanente Santa Clara Medical Center

    Santa Clara, California, 95051, United States

  • Kaiser Permanente Vallejo Medical Center

    Vallejo, California, 94589, United States

  • Missouri Baptist Medical Center

    St Louis, Missouri, 63131, United States

  • New Hampshire Oncology - Hematology, PA

    Manchester, New Hampshire, 03103, United States

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • SUNY Upstate Medical University

    Syracuse, New York, 13210, United States

  • University of California San Diego Moores Cancer Center

    La Jolla, California, 92037, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

  • University of Wisconsin

    Madison, Wisconsin, 53792, United States

  • Washington University Siteman Cancer Center

    St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.